FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 clinical trial.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/37uCrI9
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/37uCrI9